Every 8-K that OnKure Therapeutics (OKUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. approved an option repricing effective August 7, 2026, resetting the exercise price of certain underwater employee and consultant stock options granted before January 1, 2025 to $4.14 per share, the Class A common stock closing price on the effective date. The change covers approximately 1.7 million shares with prior exercise prices at or above $10.00, including sizeable grants held by the CEO, CMO, and CFO. Vesting schedules, terms, and share counts are unchanged, and a retention requirement of 18 months for senior management and one year for other participants applies; exercising before meeting this requirement triggers a premium exercise price equal to the original strike. The board states the structure is intended to refresh performance and retention incentives while avoiding additional stock dilution or cash compensation costs.
OnKure Therapeutics reported second-quarter 2026 results and progress on its PI3Kα-focused precision medicine pipeline. Lead candidates OKI-355 for vascular anomalies and OKI-345 for breast cancer are in IND-enabling activities, with Investigational New Drug submissions planned for the first half of 2027.
The company highlighted scientific engagement through a Key Opinion Leader event on PI3Kα pan-mutant inhibition and participation at the ISSVA World Congress. As of June 30, 2026, cash, cash equivalents and marketable securities were $176.4 million, expected to fund operations into 2029.
For the quarter, research and development expenses were $12.6 million for both the second quarter of 2026 and 2025, while general and administrative expenses were $4.3 million versus $3.7 million a year earlier. Net loss was $15.3 million, or $0.31 per share, compared with $15.4 million, or $1.14 per share, in the prior-year quarter.
OnKure Therapeutics held its 2026 annual stockholder meeting and approved amendments to its 2024 Equity Incentive Plan. The plan now includes a one-time increase of 3,231,638 shares of common stock, described as approximately 8% of outstanding shares, reserved for equity awards.
The annual “evergreen” feature will continue to add up to 5% of outstanding shares each year, but the prior numerical cap of 2,407,100 shares has been removed, and the number of shares eligible for incentive stock options is now limited. Shareholders also elected three Class II directors to serve until the 2029 annual meeting, ratified KPMG LLP as independent auditor for 2026, and formally approved the amended and restated 2024 Equity Incentive Plan.
OnKure Therapeutics reported first quarter 2026 results and highlighted a major capital raise and pipeline refocus. Cash and cash equivalents were $192.1 million as of March 31, 2026, including proceeds from an oversubscribed $150 million private placement, which the company expects will fund operations into 2029.
Research and development expenses were $11.7 million and general and administrative expenses were $3.9 million, both slightly lower than the prior-year quarter. Net loss was $15.2 million, or $1.11 per share, compared with $15.9 million, or $1.19 per share, a year earlier.
Strategically, OnKure nominated two next-generation PI3Kα pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with plans to submit IND applications for both in the first half of 2027. The company is not planning to independently pursue further clinical development of OKI-219 but will report data from the PIKture-01 study by the end of 2026.
OnKure Therapeutics, Inc. entered into a private placement financing with institutional investors, agreeing to sell 26,713,636 Class A common shares at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, for expected gross proceeds of about $150.0 million before fees. The company plans to use the net proceeds to advance its next-generation PI3Kα pan-mutant programs in breast cancer and vascular anomalies and for working capital and general corporate purposes.
Investors receive registration rights for resale of the shares and warrant shares, and the lead investor obtains a board designee right, under which Dr. Liam Ratcliffe will join the board as a Class I director contingent on closing. Executives and directors agreed to a lock-up, and the company agreed to restrictions on new equity issuances and certain corporate actions for at least 180 days after closing and until the resale registration is effective. OnKure also provided pipeline updates, including plans to file INDs for OKI-345 and OKI-355 in the first half of 2027, progress in the PIKture-01 Phase 1a/1b trial of OKI-219, and a decision not to pursue further independent development of OKI-219 while it focuses on its PI3Kα pan-mutant inhibitors.
OnKure Therapeutics, Inc. reported fourth quarter and full-year 2025 results alongside updates on its PI3Kα‑focused oncology pipeline. Cash and cash equivalents were $59.1 million as of December 31, 2025, compared with $110.8 million a year earlier, reflecting continued investment in clinical development.
For Q4 2025, research and development expenses were $10.7 million and general and administrative expenses were $3.4 million, both below Q4 2024 levels. Net loss for the quarter was $13.5 million, or $0.99 per share, versus $17.4 million, or $1.37 per share, in Q4 2024.
Full-year 2025 net loss was $59.5 million, or $4.40 per share. Operationally, the company highlighted progress for lead candidate OKI‑219 in the PIKture‑01 phase 1 study, including completed enrollment in early trial parts and ongoing triplet combination arms, with multiple data readouts and a next‑generation PI3Kα pan‑mutant candidate announcement expected in 2026.
OnKure Therapeutics (OKUR) entered a Sales Agreement with Leerink Partners to sell Class A common stock from time to time through an at‑the‑market offering. The company will direct sale parameters, and Leerink Partners will act as sales agent.
Leerink Partners will receive up to 3.0% of gross proceeds from shares sold under the program. OnKure has no obligation to sell and may suspend sales at any time. Either party may terminate the agreement on 10 days’ notice, with additional immediate termination rights under certain conditions. Sales will be made under a Form S‑3 shelf and its prospectus supplement and no sales may occur until the registration statement becomes effective.
OnKure Therapeutics, Inc. announced it issued a press release reporting financial results for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 alongside a business update.
The information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated into other filings unless specifically referenced.